Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer

DISEASE CHARACTERISTICS:

• Histologically or cytologically proven advanced malignancy that is refractory to prior therapy or unlikely to benefit from standard therapy (e.g., chemotherapy, radiotherapy, and surgery)

  • Part I: Previously untreated OR minimally pretreated

    • Ineligible for part I and considered heavily pretreated if:

      • Prior radiotherapy to wide ports involving the pelvis or at least 25% of bone marrow
      • Greater than 6 courses of prior combination chemotherapy including alkylating agent
      • Prior nitrosoureas or mitomycin
      • Widespread bone metastases with bone marrow involvement by bone marrow biopsy (positive bilateral bone marrow biopsy for lymphoma patients)
  • Part II: Heavily pretreated as defined above
• Measurable or evaluable disease

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• SWOG 0-2

Life expectancy:

• At least 3 months

Hematopoietic:

• Absolute neutrophil count greater than 1,500/mm^3
• Hemoglobin greater than 9 mg/dL
• Platelet count greater than 100,000/mm^3

Hepatic:

• Bilirubin less than 1.5 mg/dL

Renal:

• Creatinine less than 1.5 mg/dL

Cardiovascular:

• No uncontrolled hypertension
• No angina pectoris
• No clinically significant, multifocal, uncontrolled cardiac dysrhythmias

Other:

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active serious infection
• No clinically severe peripheral neuropathy (grade 1 or worse)
• No nonmalignant medical condition that would preclude compliance or increase risk of participation in study
• No hypersensitivity to E. coli derived drug preparations

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No other concurrent colony stimulating factors for prophylactic purposes

Chemotherapy:

• At least 3 weeks since prior chemotherapy (6 weeks since prior nitrosoureas and mitomycin) and recovered

Endocrine therapy:

• No chronic oral corticosteroids
• No concurrent corticosteroids except as prophylactic antiemetic

Radiotherapy:

• At least 3 weeks since prior radiotherapy and recovered

Other:

• At least 1 month since prior investigational agent
• No prophylactic oral or IV antibiotics for neutropenia unless fever present
• No other concurrent anticancer treatment or investigational agent